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patient-Derived cells to Guide 
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Adequate preclinical model and model establishment procedure are required to accelerate translational 
research in lung cancer. We streamlined a protocol for establishing patient-derived cells (PDC) and 
identified effective targeted therapies and novel resistance mechanisms using PDCs. We generated 
23 PDCs from 96 malignant effusions of 77 patients with advanced lung adenocarcinoma. Clinical 
and experimental factors were reviewed to identify determinants for PDC establishment. PDCs 
were characterized by driver mutations and in vitro sensitivity to targeted therapies. Seven pDcs 
were analyzed by whole-exome sequencing. PDCs were established at a success rate of 24.0%. 
Utilizing cytological diagnosis and tumor colony formation can improve the success rate upto 48.8%. 
In vitro response to a tyrosine kinase inhibitor (TKI) in PDC reflected patient treatment response and 
contributed to identifying effective therapies. Combination of dabrafenib and trametinib was potent 
against a rare BRAF K601E mutation. Afatinib was the most potent EGFR-TKI against uncommon 
EGFR mutations including L861Q, G719C/S768I, and D770_N771insG. Aurora kinase A (AURKA) 
was identified as a novel resistance mechanism to olmutinib, a mutant-selective, third-generation 
EGFR-TKI, and inhibition of AURKA overcame the resistance. We presented an efficient protocol for 
establishing PDCs. PDCs empowered precision medicine with promising translational values.
Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. Oncogenic driver 
mutations have been identified in NSCLC including epidermal growth factor receptor gene (EGFR) mutations, 
anaplastic lymphoma kinase gene (ALK) fusions, v-raf murine sarcoma viral oncogene homolog B (BRAF) muta-
tions, and ROS1 fusions. Over the last decade, small molecule tyrosine kinase inhibitors (TKI) have been devel-
oped to target these mutations, which revolutionized therapeutic landscape in NSCLC; Treatment with TKIs have 
prolonged survival and increased disease control in patients with advanced NSCLC1,2.
Unfortunately, most patients eventually relapse within a year on TKI therapy. To date, various mechanisms of 
acquired resistance to TKIs have been reported. The most common molecular mechanisms of resistance are sec-
ondary mutations in kinase domains of the drug targets and activation of alternative pathways3–5. With advances 
in molecular profiling of acquired resistance, new therapeutic strategies, such as combination targeted therapies 
and next-generation TKIs, have been introduced to overcome the TKI resistance1. On the other hand, molecular 
determinants that clearly guide subsequent therapy have not been observed in some patients who failed to pre-
vious treatment.
Drug-resistant cell lines that are established following chronic exposure to a drug in vitro are conventionally 
used for studying the mechanisms of TKI resistance in NSCLC. However, a limited panel of NSCLC cell lines 
harboring the EGFR mutation, ALK fusion, or ROS1 fusion is commercially-available. Additionally, these models 
may exhibit different patterns of drug sensitivity likely due to lack of genetic complexity found in patients6.
Patient-derived cells (PDC) generated from tumor specimens have shown to reflect patient tumor character-
istics and clinical responses7. The practical challenges for primary culture of tumor cells involve limited availa-
bility of tumor specimens, outgrowth of stromal cells, and tumor cell senescence8,9. Here, we evaluated clinical 
and experimental factors that may impact a success rate of PDC establishment, which can accelerate model 
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establishment procedure and promote translational research. We also investigated resistance mechanisms and 
novel combinational therapies to overcome resistance to third-generation EGFR-TKIs in EGFR-mutant NSCLC 
using our PDCs.
Materials and Methods
ethics approval. This study was approved by Yonsei University Hospital Institutional Review Board (Seoul, 
Korea) (IRB no.: 4-2016-0788). This study was conducted according to the Declaration of Helsinki and all patients 
provided informed consent.
Sample processing and establishment of patient-derived cells. A total of 96 malignant effusions 
(89 pleural effusions, 4 pericardial effusions, and 3 ascites) were collected from 77 patients with advanced lung 
adenocarcinoma at Yonsei Cancer Center between March 2016 and July 2018. Fluorescence in situ hybridization, 
immunohistochemistry, and direct sequencing were routinely performed for initial diagnosis of lung adenocarci-
noma. PANAMutyperTMR (Panagene, Daejeon, Korea) was routinely performed for genotyping of EGFR-mutant 
NSCLC at recurrence. Clinical data were retrieved based on electric medical record system.
All samples were kept on ice during transport from Yonsei Cancer Center to the laboratory where samples 
were processed. Ninety-two cases were assessed for malignancy by a pathologist (HS Shim), whereas four cases 
were rejected due to insufficient amount of cells. Samples that were positive for malignancy were defined as M+. 
Otherwise, samples were defined as M−.
Malignant effusions were processed as previously described10,11. In brief, samples were centrifuged at 500 g for 
10 min before cell pellets were suspended in PBS. Then, cells were separated by density gradient centrifugation 
using Ficoll-PaquePLUS (GE Healthecare Bio-Sciences, Uppsala, Sweden). Mononuclear cells including tumor 
cells were isolated from the interphase layer, washed twice with HBSS, suspended in R10 medium [RPMI-1640 
with 10% fetal bovine serum, 5% penicillin/streptomycin, and 1% primocin (Invitrogen, Massachusetts, USA)], 
and seeded on collagen IV pre-coated culture plates at a density of approximately 1 to 2 × 106 cells per plate. After 
culture initiation, cells were observed for 10 days using light microscopy. Tumor colony formation, defined by 
multiple lung adenocarcinoma cells (n ≥ 2) adherent to a culture plate, was occasionally observed in primary 
cultures (Supplementary Fig. 1)10. If such tumor colony formation was detected, a primary culture was defined 
as TCF+. Otherwise, a primary culture was defined as TCF- (Supplementary Fig. 1). Primary cultures were 
frequently contaminated with stromal cells (Supplementary Table 1). To achieve high tumor purity, differential 
trypsinization was regularly performed (Supplementary Fig. 2)7,12.
cell culture. H2291 cells were obtained from the American Type Culture Collection and MRC-5 cells were 
obtained from Korean Cell Line Bank. PC9 cells were provided by J.C. Lee (Korea Institute of Radiological and 
Medical Science, Seoul, Korea). H2291, PC9, and all PDCs were cultured in R10 medium. MRC-5 cells were 
cultured in MEM supplemented with 10% fetal bovine serum, 5% penicillin/streptomycin, and 1% primocin. All 
cells were replenished with medium every three days and maintained in a 5% CO2 incubator at 37 °C. Cells were 
passaged at ratios of 1:2 to 1:6 using TrypLE (Invitrogen).
Flow cytometry. Cells were stained with a human EpCAM antibody or a human fibroblast antibody 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Flow cytometry 
was performed using FACSVerse (BD Biosciences, California, USA) and analyzed with FlowJo software.
DnA and RnA extractions. gDNA was extracted from PDCs using the DNeasy Blood & Tissue Kits 
(Qiagen, Venlo, Netherlands). In 5 cases (YU-1088, YU-1094, YU-1095, YU-1096, and YU-1097), germline DNA 
was extracted from normal blood of corresponding patients using the DNeasy Blood & Tissue Kits (Qiagen). 
RNA was extracted from PDCs using TRIzol (Invitrogen) before being synthesized to cDNA using SuperScript 
III First-Strand Synthesis System.
Direct sequencing. EGFR sequencing service was provided by Macrogen Inc. (Seoul, Korea). EML4-ALK 
gene arrangements were PCR amplified as previously described13. CD74-ROS1, TPM3-ROS1, SLC34A2-ROS1 
genes were PCR amplified using AccuPower® PCR Premix (Bioneer, Seoul, Korea). All PCR primers used in this 
study are listed in Supplementary Table 2.
Whole-exome sequencing and data analysis. gDNA purity and concentration were tested by 
PicoGreen® dsDNA assay (Invitrogen) and agarose gel electrophoresis method. Genomic fragment library was 
prepared using SureSelect v5 Kit (Agilent Technologies, Santa Clara, CA) and then sequenced on Illumina HiSeq 
2500 (California, USA). The resulting sequencing reads were mapped to the human genome reference (hg19) using 
the Burrows-Wheeler alignment tool14,15. Somatic mutations were called using MuTect2. In 2 cases (YU-1070 
and YU-1089) which lack corresponding normal blood samples, germline variants were filtered out using 
ExAC_AF database at a frequency of >0.01. Copy number variation was analyzed by CNVkit in PDCs (YU-1088, 
YU-1094, YU-1095, YU-1096, and YU-1097) where corresponding normal blood samples were available16. 
Annotation was performed with cosmic database17,18.
cell viability assays. Cells were seeded at a density of 2500–5000 per well in 96-well clear bottom 
microplates. Cells were incubated overnight and treated with drugs for 3 days. Cell viability was analyzed using 
CellTiter-Glo (Promega, Wisconsin, USA). IC50 values were calculated using GraphPad Prism version 5. Drugs 
used in the assays were purchased from Selleckchem (Texas, USA). Combination index (CI) was calculated using 
the Chou-Talalay method and the Bliss independence model19,20. For crystal violet assays, cells were seeded at a 
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density of 20000 cells per well on 6-well plates. Cells were incubated overnight and exposed to the indicated drugs 
for 14 days. Medium containing drugs were replenished every 3 days.
immunoblot analysis. Bim, Bax, Cleaved PARP, BRAF, pCRAF (S338), CRAF, MEK, pMEK (S217/221), 
EGFR, pEGFR (Y1068), AKT, pAKT (S473), ERK, pERK (T202/Y204), AURKA, pAURKA, S6, pS6 (S240/244), 
and HRP–conjugated secondary antibodies were purchased from Cell Signaling Technology (Danvers, 
MA). Actin was obtained from Merck Millipore (Darmstadt, Germany). The immunoblots were detected by 
SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Massachusetts, USA).
Statistical analysis. In univariate analysis, the Fisher’s exact test and Mann-Whitney U test were applied to 
investigate association between PDC establishment and variables. In multivariate analysis, multivariate logistic 
regression model was used.
Results
positive cytological diagnosis of malignancy and tumor colony formation impact pDc estab-
lishment. A total of 23 PDCs were established from malignant effusions of advanced lung adenocarcinoma 
at a success rate of 24.0%. Established PDCs were free of stromal cells by light microscopy, strongly positive for 
EpCAM (an epithelial cell marker), could be frozen/thawed, and propagated at least 10 times (Supplementary 
Table 3 and Supplementary Fig. 3A)7,21,22.
Previous studies have shown that several factors including genetic alteration impact success rate of 
patient-derived xenograft model establishment, whereas little is known about establishing PDC from advanced 
lung adenocarcinoma23–25. To address this question, we reviewed association of factors to PDC establishment. 
Univariate analysis revealed that positive cytological diagnosis of malignancy (M+) and tumor colony formation 
in the initial primary culture (TCF+) were strongly correlated with PDC establishment (OR = 8.3654, P < 0.001; 
OR = 22.0772, P < 0.001) as well as multivariate analysis (OR = 4.8336, P = 0.0239; OR = 14.1733, P = 0.0131) 
(Table 1 and Supplementary Fig. 1). As expected, high concordance was observed between M+ and TCF+ group 
in malignant effusions (Fig. 1A). The success rate was high in M+/TCF+subgroup (20/41, 48.8%), implying that 
these factors may be a powerful indicator of successful model establishment (Fig. 1B). A major reason for failure 
of model establishment was a paucity of tumor cells in samples (62/73; 84.9%) followed by tumor cell senescence 
(11/73; 15.1%).
characteristics of pDcs. We characterized PDCs by direct sequencing (n = 23) and whole-exome sequenc-
ing (WES) (n = 7) (Table 2, Supplementary Table 4, and Supplementary Fig. 4). Fourteen EGFR-mutant cell lines 
were generated from EGFR-mutant tumors progressing to first- (n = 8), second- (n = 1), or third-generation 
EGFR-TKIs (n = 5). Routine genetic testing of rebiopsy samples at recurrence were available in 9 patients with 
EGFR-mutant NSCLC. Notably, EGFR genotypes detected in the rebiopsy samples were concordant to those 
in corresponding PDCs (Table 2). Three PDCs which were originated from ALK-positive NSCLC maintained 
EML4-ALK fusion genes. Five ROS1-fusion PDCs which were generated from ROS1-positive NSCLC maintained 
various ROS1 fusion genes (SLC34 A2-ROS1, CD74-ROS1, and TPM3-ROS1) (Table 2). WES identified BRAF 
K601E as a driver mutation in YU-1070 cells that were derived from NSCLC without druggable genomic altera-
tions (Supplementary Table 4 and Supplementary Fig. 4A). These results demonstrate that PDCs largely maintain 
known patient driver mutations.
Extensive passaging may result in a genetic drift of cell lines26,27. To investigate this issue, we analyzed 5 PDCs 
at early and later passages using direct sequencing (YU-1092, YU-1096, YU-1152, and YU-1097) or WES (YU-
1094). A mutation allele frequency (MAF) of EGFR mutations were preserved upto approximately 30 passages 
(Supplementary Fig. 4B). Furthermore, somatic mutations and copy number variations were stably maintained 
between passages (Supplementary Fig. 4A,C, and D). These results may suggest that driver mutations and 
tumor-related genes are stably maintained at least in tested PDCs.
Next, we compared in vitro sensitivity to TKI in PDC with response in the clinic. Ten patients in our study 
received subsequent TKI therapy after PDC establishment (5 osimertinib, 3 first-generation EGFR-TKI, 2 
entrectinib). Twelve PDCs established from these patients were screened with TKI which the patients were 
treated with (Fig. 2A). Two out of five patients with EGFR-mutant NSCLC were positive for EGFR T790M muta-
tion, a marker of sensitivity to osimertinib, and received clinical benefits from osimertinib therapy, achieving a 
partial response (PR) and relatively long progression-free survival (PFS)3. Two corresponding PDCs (YU-1090 
and YU-1073) exhibited in vitro sensitivity to osimertinib. Three PDCs (YU-1093, YU-1152, and YU-1094) 
generated from patients who were treated with osimertinib and had progressive disease as a best response 
were resistant to the drug (Fig. 2B). Three patients who received first-generation EGFR-TKI treatment did not 
achieve a partial response and had short PFS (n = 3). Accordingly, 4 corresponding PDCs (YU-1088, YU-1099, 
YU-1095, and YU-1091) were not responsive to gefitinib (Fig. 2C). Two patients with ROS1-positive NSCLC 
received entrectinib. One patient experienced a partial response with PFS of 6.5 months and corresponding PDC 
(YU-1080) was sensitive to entrectinib (Supplementary Fig. 3B). The other patient displayed cardiac toxicity to 
entrectinib therapy [not evaluable according to RECIST (Response Evaluation Criteria In Solid Tumors)] and 
switched to crizotinib. PFS on crizotinib was 4.2 months, indicating intrinsic resistance to the therapy (Fig. 2D). 
YU-1082 and YU-1083 cells were established from the patient before the start of crizotinib therapy and were 
resistant to the drug in vitro. A similar pattern was observed for YU-1085 cells that were established from the 
patient after crizotinib therapy (Fig. 2D and E). Together, these data suggest that PDCs may reflect patient treat-
ment response to TKI.
PDCs can guide the selection of potentially effective therapy in oncogene-driven lung adenocar-
cinoma. BRAF mutations are found in 1–3% of lung adenocarcinoma2. The two main types of BRAF mutations, 
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V600E and non-V600E, are associated with different clinicopathological features of lung adenocarcinoma and 
exhibit different therapeutic response to BRAF-targeted targeted agents1,28. While dabrafenib alone or in combi-
nation with trametinib demonstrated promising efficacy in BRAF V600E mutant NSCLC, appropriate treatment 
paradigms are still under investigation for non-V600E mutations29,30.
To identify an effective therapy for treatment of non-V600E BRAF mutant NSCLC, we tested efficacy of the 
single-agent and combination targeted therapy in YU-1070 cells harboring a BRAF K601E mutation. YU-1070 
cells were highly resistant to vemurafenib, dabrafenib, and trametinib (Supplementary Fig. 5A). On the other 
hand, treatment with trametinib sensitized YU-1070 cells to dabrafenib (Fig. 3A). The combination of dabrafenib 
with trametinib induced c-Raf phosphorylation and completely blocked ERK phosphorylation (Fig. 3B). These 
data demonstrate that the BRAF K601E mutation may respond to the dabrafenib/trametinib combination therapy.
Most NSCLC patients harboring common EGFR mutations, such as deletions in exon 19 or the L858R muta-
tion in exon 21, respond dramatically to EGFR-TKIs. However, there is a paucity of data regarding the activity of 
Variate
PDC establishment
Pa OR (95% CI)No (n = 73) Yes (n = 23)
Univariate analysis
Age 57 (19–88) 57 (19–77) 0.6031b
Gender 0.7585 (0.2647–2.1520)
   Female 40 (78.4%) 11 (21.6%) 0.6352
   Male 33 (73.3%) 12 (26.7%)
Prior therapy 0.3005 (0.0206–4.3759)
   Yes 71 (77.2%) 21 (22.8%) 0.2417
   No 2 (50.0%) 2 (50.0%)
Prior chemotherapy 0.4745 (0.1626–1.3841)
   Yes 51 (81.0%) 12 (19.0%) 0.1367
   No 22 (66.7%) 11 (33.3%)
Prior TKI therapy 1.0289 (0.2727–4.8489)
   Yes 60 (75.9%) 19 (24.1%) 1
   No 13 (76.5%) 4 (23.5%)
EGFR mutation 0.5904 (0.1994–1.8049)
   Yes 53 (79.1%) 14 (20.9%) 0.3064
   No 20 (69.0%) 9 (31.0%)
ALK fusion 0.9455 (0.1524–4.1794)
   Yes 10 (76.9%) 3 (23.1%) 1
   No 63 (75.9%) 20 (24.1%)
ROS1 fusion 3.0575 (0.6588–13.6332)
   Yes 6 (54.5%) 5 (45.5%) 0.1259
   No 67 (78.8%) 18 (21.2%)
Source 1.9584 (0.2184–94.6450)
   Pleural effusion 67 (75.3%) 22 (24.7%) 1
   Others 6 (85.7%) 1 (14.3%)
Time to processing 1.9584 (0.2184–94.6450)
   <4 hours 67 (75.3%) 22 (24.7%) 1
   >24 hours 6 (85.7%) 1 (14.3%)
Sample volume 200 (10–1350) 200 (60–500) 0.58232b
Cytology 8.3654 (2.1991–47.7354)
   Malignancy 32 (61.5%) 20 (38.5%) <0.001
   Others 41 (93.2%) 3 (6.8%)
Tumor colony formation 22.0772 (3.2262–953.2819)
   Yes 36 (62.1%) 22 (37.9%) <0.001
   No 37 (97.4%) 1 (2.6%)
Multivariate analysisc
Variate P OR (95% CI)
Malignancy vs others 0.0239 4.8336 (1.2322–18.9608)
Tumor colony formation vs no colony formation 0.0131 14.1733 (1.7469–114.9934)
Table 1. Univariable and multivariable analyses for determining factors correlated to PDC establishment. aThe 
P value is calculated using the Fisher’s exact test unless indicated otherwise. bThe P value is calculated with the 
Mann-Whitney U test. cThe P value and odd ratio are analyzed by multivariate logistic regression. PDC, patient-
derived cells.
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EGFR-TKIs in NSCLC harbor uncommon EGFR mutations, such as G719X, L861Q, S768I alone or in combina-
tion with each other, which occur in approximately 10% of EGFR-mutant NSCLC31.
To select the best treatment, we tested efficacy of EGFR-TKIs in YU-1092 cells (EGFR L861Q) and YU-1099 
cells (EGFR G719C/S768I). Both YU-1092 and YU-1099 cells were resistant to gefitinib (Fig. 3C and D). Afatinib 
was the most potent drug with IC50 values of 6 nmol/L (EGFR L861Q) and 106 nmol/L (EGFR G719C/S768I) 
(Fig. 3C). Osimertinib was moderately effective against EGFR L861Q (IC50 = 75 nmol/L) and ineffective against 
the G719C/S768I complex mutation (IC50 = 836 nmol/L) (Fig. 3C). Afatinib more potently decreased EGFR and 
S6 phosphorylation compared with gefitinib and osimertinib in YU-1099 cells (Fig. 3D).
EGFR exon 20 insertions are among the rarer EGFR mutations (approximately 9% of EGFR-mutant NSCLC 
patients) and treatment for these mutations remain elusive without an approved inhibitor32,33. To identify optimal 
EGFR-TKIs, we investigated YU-1074 cells harboring the EGFR D770_N771insG mutation (Fig. 3C). Afatinib 
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Figure 1. Factors critical to establishing PDCs of advanced lung adenocarcinoma. (A) Sankey plot visualizes 
correspondence between positive cytological diagnosis of malignancy (left) and tumor colony formation 
within 10 days of culture initiation (right) in malignant effusions. (B) Bar graph shows success rates of PDC 
establishment for total (n = 96) or M+/TCF+ samples (n = 41).
Cell line 
ID Prior TKI therapyb Driver mutation
YU-1073 Gefitinib EGFR L858R/T790Ma
YU-1074 Gefitinib EGFR D770_N771insG
YU-1090 Gefitinib EGFR L858R/T790Ma
YU-1092 Gefitinib EGFR L861Q
YU-1093 Erlotinib EGFR exon 19 deletiona
YU-1094 Gefitinib EGFR L858Ra
YU-1099 Gefitinib EGFR G719C/S768Ia
YU-1152 Erlotinib EGFR L858Ra
YU-1091 Afatinib + Ruxolitinib EGFR L858Ra
YU-1088 Osimertinib EGFR exon 19 deletiona
YU-1089 Olmutinib EGFR exon 19 deletiona
YU-1095 Osimertinib EGFR exon 19 deletiona
YU-1096 Osimertinib EGFR L858R
YU-1097 Osimertinib EGFR exon 19 deletion/T790M/C797S
YU-1080 N/A CD74-ROS1
YU-1081 Crizotinib TPM3-ROS1
YU-1082 N/A SLC34A2-ROS1
YU-1083 N/A SLC34A2-ROS1
YU-1085 Crizotinib SLC34A2-ROS1
YU-1075 Crizotinib EML4-ALK
YU-1076 Ceritinib EML4-ALK
YU-1077 Alectinib EML4-ALK G1202R
YU-1070 N/A BRAF K601E
Table 2. Characteristics of PDCs. aRoutine genetic testing results were available in re-biopsy samples after 
disease progression in these cases and confirmed driver mutations detected in corresponding PDCs. bPDC was 
generated from advanced lung adenocarcinoma progressing to the annotated therapy. N/A, not available.
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potently inhibited growth of YU-1074 cells, whereas osimertinib was less effective than afatinib (Fig. 3C). 
Together, these data suggest that afatinib among all EGFR-TKIs tested may be the most effective treatment for the 
uncommon EGFR mutations.
EGFR C797S mutation is one of the most commonly reported mechanisms of acquired resistance to 
third-generation EGFR-TKIs5. EGFR T790M mutation in cis to C797S mutation confers resistance to 
third-generation EGFR-TKIs as well as first-generation EGFR-TKIs34. A combination of brigatinib and cetuximab 
has been introduced to overcome the C797S-mediated resistance35. We aimed to evaluate EGFR-TKI efficacies in 
YU-1097 cells harboring an EGFR exon 19 del/T790M/C797S mutation (T790M in cis to C797S). YU-1097 cells 
were resistant to single-agent gefitinib, afatinib, osimertinib, and brigatinib (Supplementary Fig. 5B). Notably, 
YU-1097 cells were highly sensitive to the combination of brigatinib and cetuximab (Fig. 3E). The drug combi-
nation synergistically suppressed phosphorylation of AKT and ERK (Fig. 3F). These results show that the triple 
mutation may respond to the brigatinib/cetuximab combination therapy.
AURKA as a potential therapeutic target in EGFR-mutant nScLc resistant to third-generation 
eGfR-tKi. Mechanisms of drug resistance remains elusive in 47–60% of patients with EGFR-mutant NSCLC 
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TKI therapy
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Best response 
by 
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clinic vs in vitro 
sensitivity
YU-1090 L858R/T790M 37 Gefitinib Osimertinib PR 8.8 Matching
YU-1073 L858R/T790M 47 Gefitinib Osimertinib PR 11.7 Matching
YU-1093 Exon 19 deletion 397 Erlotinib Osimertinib PD 0.7 Matching
YU-1152 L858R 705 Erlotinib Osimertinib PD 0.7 Matching
YU-1094 L858R 1519 Gefitinib Osimertinib PD 1.2 Matching
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clinic vs in vitro 
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YU-1088 Exon 19 deletion 765 Osimertinib Gefitinib SD 7.0 Matching
YU-1099 G719C/S768I 1148 Gefitinib Erlotinib SD 5.6 Matching
YU-1095 Exon 19 deletion 1953 Osimertinib Gefitinib SD 7.0 Matching
YU-1091 L858R 5264 Afatinib+Ruxolitinib Erlotinib SD 2.5 Matching
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Figure 2. PDC modeling of patient treatment response to TKIs. (A) Twelve PDCs were established from 10 
patients who received subsequent TKI therapy. Clinical follow-up data were retrospectively collected. At the 
same time, PDCs were screened with TKI which the patients received. In vitro sensitivity to the TKI in the PDC 
and response in the clinic were compared. (B) Summary of 5 EGFR-mutant PDCs which were generated from 
patients treated with osimertinib as subsequent TKI therapy. (C) Summary of 4 EGFR-mutant PDCs which 
were generated from patients treated with a first-generation EGFR-TKI as subsequent TKI therapy. (D) Clinical 
course of a patient with ROS1-positive NSCLC. YU-1082, YU-1083, and YU-1085 cells were derived from 
patient tumors at the indicated time points. (E) YU-1082, YU-1083, and 1085 cells were treated with the 
indicated concentrations of crizotinib. Data are presented as the mean ± SEM (n = 3). PR, partial response; PD, 
progressive-disease; SD, stable disease; PFS, progression-free survival.
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Figure 3. PDCs can guide the selection of potentially effective therapy in oncogene-driven lung 
adenocarcinoma. (A) YU-1070 cells were treated with the indicated concentrations of trametinib alone or 
in combination with dabrafenib. (ANOVA with Dunnett’s post test: *p < 0.05, ***p < 0.001 vs the value in 
DMSO control, ###p < 0.05 vs the value at the indicated comparison, n = 3) (B) YU-1070 cells were treated with 
the indicated concentrations of trametinib alone or in combination with dabrafenib for 1 hour. Cell lysates 
were immunoblotted with the indicated antibodies. (C) YU-1092, YU-1099, and YU-1074 cells were treated 
with the indicated concentrations of gefitinib, afatinib, or osimertinib. Data are presented as the mean ± SEM 
(n = 3) (two-tailed Student t-test: *p < 0.05, **p < 0.005 vs the value at the indicated comparison). n.s., not 
significant. (D) YU-1099 cells were treated with indicated concentrations of gefitinib, afatinib, or osimertinib 
for 24 hours. Cell lysates were immunoblotted with the indicated antibodies. (E) YU-1097 cells were treated 
with the indicated concentrations of brigatinib alone or in combination with cetuximab for 2 weeks. Colony 
formation was stained by crystal violet (upper panel). The bar graph shows quantification of the crystal violet 
staining (lower panel). (ANOVA with Dunnett’s post test: *p < 0.05, ***p < 0.001 vs the value in negative 
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progressing to third-generation EGFR-TKIs, posing a challenge to clinical decision making for these patients36,37. 
Using our clinically-relevant cell lines, we aimed to provide therapeutic strategies in this setting. In our panel of 
PDCs resistant to third-generation EGFR-TKIs, WES revealed genetic alterations (EGFR C797S, MET amplifica-
tion, PIK3CA amplification, and PTEN loss) associated with osimertinib resistance36–38. However, known genetic 
alteration associated with drug response was not observed in YU-1089 cells (Fig. 4A, Supplementary Fig. 4A and E). 
First-, second-, and third-generation EGFR-TKIs failed to inhibit growth of YU-1089 cells (Fig. 4B). The 
EGFR-TKIs suppressed phosphorylation of EGFR and ERK but had no effect on phosphorylation of AKT (Fig. 4C).
To overcome the EGFR-independent mechanism of olmutinib resistance using YU-1089 cells, we comprised a 
panel of 79 investigational or FDA-approved drugs which target a wide range of kinases (Supplementary Table 5). 
Then, we performed drug combination screening on YU-1089 cells with olmutinib and each drug in the panel to 
nominate potent drug combinations. The screening identified 41 drugs with synergistic effects (CI < 1). The most 
strong synergy was observed with tozasertib, which targets Aurora kinases (Fig. 4D)39.
We next characterized the synergistic effect of combined EGFR and aurora kinase inhibition. The combina-
tion of olmutinib with tozasertib potently inhibited colony formation of YU-1089 cells compared to either agent 
alone (Fig. 4E). The robust synergism was confirmed in a 5 × 5 dose response matrix by using the Chou-Talalay 
method, resulting in a combination index (CI) value of 0.029 at 50% growth inhibition. Furthermore, the com-
bination of olmutinib with tozasertib synergistically decreased phosphorylation of AKT and ERK and increased 
expression of apoptotic markers in YU-1089 cells. The comparable antitumor synergy was also shown by a com-
bination of olmutinib with alisertib, a highly selective Aurora A kinase inhibitor under clinical development 
(CI = 0.196 at 44% growth inhibition), and a combination of osimertinib with tozasertib (CI = 0.189 at 52% 
growth inhibition) (Supplementary Fig. 7A)40. Recently, Shah et al. has shown that AURKA confers resistance 
to third-generation EGFR-TKIs in NSCLC and inhibition of AURKA can resensitize the tumor to EGFR-TKIs41. 
Thus, we tested if this drug combination strategy is applicable to other osimertinib-resistant PDCs. However, the 
osimertinib/alisertib combination was less potent in YU-1095, YU-1096, and YU-1097 cells than in YU-1089 
cells (Supplementary Fig. 7B). These differential responses to combined EGFR and AUKRA inhibition may be 
due to difference in AURKA expression41,42. Supporting this hypothesis, AURKA expression was lower in PDCs 
that were not responsive to the drug combination (Supplementary Fig. 7C)41,42. Together, these results suggest 
that Aurora kinase A may be an actionable therapeutic target to overcome acquired resistance to third-generation 
EGFR-TKIs in EGFR-mutant NSCLC.
Discussion
In this study, we established 23 PDCs that represent molecularly heterogeneous subsets of advanced lung adeno-
carcinoma. Among them, cell lines of ROS1 fusions with various fusion partners, uncommon EGFR mutations, 
a resistant C797S mutation, and a rare BRAF mutation were included (Table 2)5,43. To the best of our knowledge, 
there are no commercially-available NSCLC cell lines endogenously harboring these mutations. Using novel cell 
lines, we presented effective therapeutic strategies which may inform future clinical decision making.
Selection of appropriate tumor specimens is important for successfully establishing patient-derived mod-
els23,24. Previous studies have shown that tumor cellularity in malignant effusions of NSCLC is highly variable, 
ranging from 0.1% to 90%44. Furthermore, cytological diagnosis of malignant effusions can be misleading because 
of potential mimics such as reactive mesothelial cells45. To use the malignant effusion as starting material, there is 
an urgent need to optimize establishment procedures. Our findings provided the evidence that both positive cyto-
logical diagnosis of malignancy (M+) and tumor colony formation (TCF+) were crucial to establishing PDCs 
from malignant effusions. Indeed, using M+/TCF+ malignant effusions can increase the success rate of PDC by 
approximately 2-fold (24.0% vs 48.8%). Additionally, M−/TCF−, M−/TCF+, and M+/TCF− malignant effu-
sions (55/96, 57.3%) that have a low potential for establishing PDCs (3/55; 5.5%) can be excluded in a stepwise 
manner, thereby substantially reducing time and effort needed for sample processing and subsequent long-term 
culture. Carter et al. has shown that tumor cellularity in malignant effusions of advanced NSCLC is not correlated 
to sample volume44. Accordingly, we observed sample volume did not impact cytological diagnosis (P = 0.42372) 
or PDC establishment (P = 0.58232) (Table 1 and Supplementary Fig. 9). Although the difference was not statis-
tically significant (OR = 0.5904, P = 0.3064) (Table 1), we observed a higher success rate in EGFR wild-type cases 
(31.0%) than EGFR mutant cases (20.9%). Similarly, John et al. and our group reported the negative correlation 
between EGFR mutations and NSCLC PDX model establishment from surgical resection, which may reflect a 
favorable prognostic value of EGFR mutations46–48. Interestingly, we noted tumor cell senescence in some M+/
TCF+ primary cultures (11/41; 26.8%) between 4 to 7 passages. Despite high tumor purity, 5 PDCs became 
senescent between 10 to 23 passages, whereas other PDCs stably propagated over serial passage (Supplementary 
Table 3). These results show that some advanced lung adenocarcinoma (16/41; 39.0%) may depend on niche fac-
tors, which are not provided by R10 medium or autocrine signaling, for optimal growth. Notedly, recent study has 
utilized Wnt, FGF7, and FGF10 to establish NSCLC organoid models49. The success rate for organoids was higher 
than the success rate for PDX or PDC, implying that these specific factors may be associated with niche factor 
dependency observed in the subset of advanced lung adenocarcinoma48,49. Direct comparison between these 
control, #p < 0.05 vs the value at the indicated comparison, n = 3). (F) YU-1097 cells were treated with the 
indicated concentrations of brigatinib alone or in combination with cetuximab for 6 hours. Cell lysates were 
immunoblotted with the indicated antibodies. (A and C) Cell viability was measured by CellTiter-Glo. Data 
are presented as the mean ± SEM (n = 3). (B, D, and F) Immunoblots are representative of 3 independent 
experiments. The full-length blots can be found in Supplementary Fig. 6.
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Figure 4. Aurora kinase A as a potential therapeutic target in EGFR-mutant NSCLC resistant to olmutinib. 
(A) Summary of WES analysis in PDCs resistant to third-generation EGFR-TKIs. Known mechanisms of 
resistance to osimertinib are shown. (B) Inhibition of YU-1089 cells by gefitinib (IC50 = 2,162 nmol/L), erlotinib 
(IC50 = 1,231 nmol/L), afatinib (IC50 = 275 nmol/L), dacomitinib (IC50 = 244 nmol/L), neratinib (IC50 = 275 
nmol/L), olmutinib (IC50 = 857 nmol/L), osimertinib (IC50 = 1,013 nmol/L), and nazartinib (IC50 = 3,908 
nmol/L). Cell viability was measured by CellTiter-Glo. Data are presented as the mean ± SEM (n = 3). (C) YU-
1089 cells were treated with the indicated concentrations of gefitinib, afatinib, or osimertinib for 6 hours. Cell 
lysates were immunoblotted with the indicated antibodies. Immunoblots are representative of 3 independent 
experiments. (D) Combinatorial drug screening with 1 μM of olmutinib and 1 μM of each kinase inhibitor from 
the drug library was performed on YU-1089 cells to identify potent drug combinations. The x axis represents a 
number of kinase inhibitors used in this screen. The y axis represents combination index (CI) determined by the 
Bliss independence model. Each dot is the resulting CI for the individual drug. Gray dots indicate drugs with 
antagonism (CI > 1), whereas black dots indicate drugs with synergism (CI < 1). Tozasertib (red) exhibited the 
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patient-derived models may provide insight into tumorigenesis of NSCLC and therapeutic potential for targeting 
these niche factors and related signaling pathways.
To demonstrate clinical relevance, we tested efficacy of single-agent or combination targeted therapies in 
our PDCs harboring a BRAF K601E mutation and uncommon EGFR mutations (L861Q, G719C/S768I, D770_
N771GinsG). Our data suggest that the BRAF K601E mutation may respond to a combination of dabrafenib and 
trametinib in a similar manner to a BRAF V600E mutation29. Indeed, the drug combination has demonstrated 
efficacy in a PDX model of BRAF K601E mutated melanoma50. Generally, NSCLC with uncommon EGFR muta-
tion has been known to be less sensitive to first-generation EGFR-TKIs31,51,52. Similar to our findings in a PDC 
harboring the L861Q mutation, afatinib has shown lower IC50 values than first- or third-generation EGFR-TKIs 
in genetically-engineered Ba/F3 cells31,53,54. To our knowledge, we first reported in vitro efficacy of EGFR-TKIs 
against the EGFR G719C/S768I mutation and demonstrated that afatinib was the most potent among other 
EGFR-TKIs against the EGFR G719C/S768I mutation. These previous findings and ours corroborate the clinical 
activity of afatinib in patients with the uncommon mutations with an overall response rate (ORR) of 71.1% and 
median PFS of 10.7 months32.
However, we noted that IC50 values of osimertinib in YU-1092 cells and YU-1074 cells were comparable to 
the reported mean plasma concentration in patients receiving osimertinib (≈120 nmol/L), suggesting a poten-
tial of osimertinib against these mutations55. Consistent with our preclinical findings, osimertinib was shown 
to achieve an ORR of 60% in 5 patients with NSCLC harboring uncommon EGFR mutations (G719X, G719X/
S768I, and L861Q)56. Additionally, nazartinib, a third-generation EGFR-TKI, also demonstrated preclinical 
activity against major variants of EGFR exon 20 insertions (D770_N771insSVD, V769_D770insASV, and H773_
V774insNPH)57. More recently, a patient with lung adenocarcinoma harboring EGFR exon 20 insertion (S768_
D770dup) was shown to respond to osimertinib58. Together, patients with NSCLC harboring an EGFR L861Q or 
D770_N771insG mutation may respond to osimertinib.
To date, heterogeneous mechanisms of osimertinib resistance have been reported5. Our data suggest that 
EGFR C797S-mediated resistance can be overcome by a combination of brigatinib and cetuximab, consistent with 
the previous finding35. Recent study has shown that overexpression of AURKA and its upstream TPX2 confers 
resistance to osimertinib and rociletinib41. Indeed, we found that combined inhibition of EGFR and AURKA is 
efficacious in YU-1089 cells that were established from patient tumor progressing to olmutinib (Fig. 4). It is plau-
sible that YU-1089 cells responded to tozasertib and alisertib due to elevated expression of AURKA41,42.
We observed that EGFR-TKI treatment in EGFR-mutant PDCs increases total EGFR protein (Fig. 3D,F and 4C). 
Previous studies and ours imply that this phenomenon may be common among EGFR-TKI resistant cell lines, 
although a molecular mechanism behind the phenomenon remains unclear34,35. It is well established that inhi-
bition of receptor tyrosine kinase (RTK) signaling pathway causes temporary relief of RTK-dependent negative 
feedback mechanisms, resulting in a rebound in RTK expression or downstream signaling activation59,60. EGFR 
signaling is regulated by various EGFR inducible negative regulators such as LRIG1, MIG6, SOCS4, and SOC561. 
Furthermore, LRIG1 and MIG6 are overexpressed in EGFR-mutant NSCLC cell lines and function as a negative 
regulator of EGFR signaling61–63. These findings may suggest a possible involvement of EGFR inducible negative 
regulators in EGFR upregulation after EGFR-TKI treatment. Further studies are required to investigate mecha-
nisms of the EGFR rebound and its relationship to EGFR-TKI resistance59,60.
This study had several limitations. Previous studies have demonstrated that long-term culture of patient-derived 
models results in accumulation of somatic mutations and subclonal selection. Occasionally, these genetic drifts 
may functionally impact drug sensitivity26,27. PDCs in our study varied in their growth rates and time they take 
to achieve high tumor purity (Supplementary Table 3). We observed that majority of PDCs at early passages (1 to 
8, median passage number of 3) were contaminated with fibroblasts (0%–51.9%, median value of 3.94%) in line 
with previous findings (Supplementary Table 1)8. Because of differential trypsinization, fibroblasts did not over-
grow tumor cells, although fibroblast contamination generally resulted in additional cell passaging and a delay in 
functional tests (Supplementary Tables 1 and 3). Particularly, drug testing in 1 PDC was only available after 20 
passages, which may not well represent patient tumor. Therefore, improved culture conditions should be tested in 
M+/TCF+ malignant effusions to accelerate tumor growth and turn-around time for functional assays. We also 
acknowledge that the presented therapeutic strategies should be validated in prospective clinical studies.
In summary, we streamlined a protocol for establishing PDCs and showed that these PDCs can be valuable 
preclinical platforms for designing therapeutic strategies.
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Materials and data are available upon reasonable request to corresponding authors.
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strongest synergistic effect. The screening identified 41 drugs with synergistic effects (CI < 1). (E) YU-1089 cells 
were treated with olmutinib alone, tozasertib alone, or a combination of olmutinib with tozasertib for 2 weeks. 
Colony formation was stained by crystal violet (upper panel). The bar graph (lower panel) shows quantification 
of the crystal violet staining. (ANOVA with Dunnett’s post test: ***p < 0.001 vs the value in negative control, 
###p < 0.001 vs the value at the indicated comparison, n = 3). (F) YU-1089 cells were treated with the indicated 
concentrations of tozasertib or in combination with olmutinib for 24 hours. Cell lysates were immunoblotted 
with the indicated antibodies. Immunoblots are representative of 3 independent experiments. The full-length 
blots can be found in Supplementary Fig. 8.
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